patent.fyi
Applications  /  US 2026/0355251
United States Patent Application Publication

US 2026/0355251 A1

Published
Nov 12, 2026
Filed
Jun 22, 2026
Earliest date on the face
Dec 22, 2023
Classification
A61K 35/28
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Follicle-directed cell microdepots

What ifWhat if a preparation used 1×10⁵ cells distributed in small deposits around selected hair follicles?
Claim language“between about 5×105 and about 2.5×107”

Small intradermal deposits concentrate the cells in a limited treatment area. The short distance between each deposit and nearby follicles limits how far cell-secreted factors travel through the dermis.

1.1Fresh adipose stromal fraction

What ifWhat if a freshly separated adipose stromal vascular fraction supplied the cells without culture expansion?
Claim language“isolated and expanded”

Processing adipose tissue releases a mixed cell fraction that contains stromal progenitors, endothelial cells, and other cells. The freshly recovered fraction supplies cells that release local signaling factors after placement in the scalp.

1.1Cultured follicular dermal papilla cells

What ifWhat if cultured dermal papilla cells from hair follicles supplied the cellular component?
Claim language“adipose-derived stem cells (ADSCs) or bone marrow-derived mesenchymal stem cells (MSCs)”

Cells recovered from the base of donor hair follicles form three-dimensional aggregates in low-adhesion culture wells. The aggregates provide local signals to neighboring follicular epithelial cells that regulate hair shaft formation.

1.1Low concentration local ATP

What ifWhat if the formulation contained 10 μM ATP and was placed close to the target follicles?
Claim language“50 μM to 250 μM”

Small intradermal deposits position ATP near follicular cells that express ATP-sensitive receptors. Extracellular enzymes break down ATP, giving the receptor stimulus a limited duration.

1.1Direct adenosine receptor signaling

What ifWhat if adenosine replaced ATP as the dissolved signaling molecule?
Claim language“adenosine triphosphate (ATP)”

Adenosine dissolved in the vehicle binds adenosine receptors on follicular dermal papilla cells. Activation of the A2B receptor increases intracellular cyclic AMP and supports production of fibroblast growth factor 7, which signals to follicular epithelial cells.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Ex vivo veterinary follicle assay

An isolated canine hair follicle sits in a culture insert above expanded adipose-derived stromal cells suspended in culture medium with dissolved ATP. The porous membrane retains the stromal cells in the lower chamber and permits soluble factors to pass between chambers. Serial brightfield images track hair shaft elongation against matched wells containing ATP without stromal cells.

Component substitution

Platelet lysate replaces dissolved ATP

Cell-free platelet lysate replaces the separately added ATP in an in vitro follicle assay. Expanded adipose-derived stromal cells are suspended in a defined basal medium, and clarified platelet lysate is mixed into the suspension. Parallel follicle cultures receive the complete suspension or the same volume of lysate in basal medium to distinguish the response to the combination from the response to the lysate alone.

Parameter or scale variation

Microwell scale for follicle screening

A 96-well plate holds 200 µL of culture medium per well. Each test well contains 20,000 expanded adipose-derived stromal cells and 20 µM ATP, with one isolated follicle positioned in a permeable insert. Replicate wells receive the same preparation, and images collected at 0, 24, and 48 hours provide shaft elongation measurements.

Combination with existing systems

Recirculating perfusion for follicle culture

A low-flow pump recirculates culture medium between a reservoir and a chamber containing an isolated hair follicle. Expanded bone marrow-derived mesenchymal stromal cells occupy a side chamber behind a cell-retaining membrane, and dissolved ATP enters through the reservoir. Medium flows past the membrane and through the follicle chamber, carrying soluble factors while the stromal cells remain in the side chamber.

Automated or data-driven variant

Automated preparation from viable cell counts

An image-based cell counter measures viable cell concentration in an expanded adipose-derived stromal cell suspension. Liquid-handling software uses that measurement and the ATP stock concentration to calculate the cell suspension, ATP stock, and culture medium volumes for each assay well. A robotic pipettor mixes the cell stock before aspiration, dispenses the calculated volumes, and records them against the well identifiers.

ATP monitoring in follicle culture

A liquid handler transfers small medium samples from replicate follicle cultures containing expanded stromal cells and dissolved ATP into a separate assay plate. A luciferase assay and a calibration curve prepared in the same medium convert luminescence readings to extracellular ATP concentrations. Software calculates a stock volume when the measured concentration falls below the lower control limit and adds the supplement to the culture wells to restore the target concentration.

Specific version of a part

Expanded adipose stromal cells

Adipose-derived stromal cells attach to a tissue culture surface and expand through serial passages. A viability count sets the fill at 2×10⁶ viable cells per vial.

ATP at one hundred micromolar

A sterile aqueous stock of ATP disodium salt is mixed into the cell suspension to give a final ATP concentration of 100 μM. The formulation volume includes both the ATP stock and the cell suspension.

Albumin buffered saline vehicle

Sterile isotonic saline contains 10 mM phosphate buffer at pH 7.4 and 0.5% human serum albumin by mass per volume. The buffer controls pH, and the albumin reduces cell adhesion to the vial and syringe surfaces.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2017/0216177 A1
Published
Aug 3, 2017
Filed
May 10, 2016
Class
A61K 8/4953
Document BUS 2020/0222296 A1
Published
Jul 16, 2020
Filed
Jan 15, 2020
Class
A61K 8/55
Claim 1
Document A
Document B
1.1between about 5×105 and about 2.5×107 isolated and expanded adipose-derived stem cells (ADSCs) or bone marrow-derived mesenchymal stem cells (MSCs), 50 μM to 250 μM adenosine triphosphate (ATP), and a pharmaceutically acceptable vehicle.
A topical pharmaceutical composition comprising: a) a therapeutic amount of minoxidil or a pharmaceutically acceptable derivative thereof; b) a therapeutic amount of a stem cell activating hair growth/regrowth promoter, which is an aqueous composition including about 50-55% (wt/wt) Glycerin, about 1′% (wt/wt) Larix Europaea Wood Extract, about 1% (wt/wt) Glycine, about 0.1% (wt/wt) Zinc Chloride, about 0.1% (wt/wt) Camellia Sinensis Leaf Extract and 45-50% (wt/wt) purified wa
A · US 2017/0216177 A1 · claim 4
The composition comprises a primer for skin cell mitochondrial function, such as a Krebs cycle intermediate, a precursor of a Krebs cycle intermediate, salts or esters thereof, or combinations thereof. The composition may also include antioxidants for free radical regulation and a pharmaceutically acceptable topical vehicle, such as an emollient base for skin health.
B · US 2020/0222296 A1 · ¶ 7

An empty cell means only that no passage was reproduced there.

Statements in these documents
The invention more particularly relates to a hair regrowth and growth stimulant containing Minoxidil in a non-irritating carrier formulation useful for all hair types, ethnicities and types of alopecia.
A · US 2017/0216177 A1 · ¶ 2
However, adverse effects have been reported with MTS primarily due to irritation of the scalp, such irritation manifesting as dryness, scaling, itching and redness, which occurs in approximately 7% of patients who use the 2% solution and a greater percentage of those who use the 5% solution because of its higher content of propylene glycol as well as alcohol contents of about 60%.
A · US 2017/0216177 A1 · ¶ 5
This is normally a difficult proposition for water soluble active ingredients, such as ascorbic acid, because the stratum corneum is a good water barrier.
B · US 2020/0222296 A1 · ¶ 5
Preferably, a gastric acid secretion inhibitory coating is applied to the effective amount of ATP in a manner that protects the ATP from degradation by gastric juices.
B · US 2020/0222296 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0355251 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355251/, SHA-256 3eff7b20e97ec975f75ca031f33a88bbf868a883144a59b62cf1763019e5fefa
First published
Permanent addresshttps://patent.fyi/US20260355251/
Content fingerprint (SHA-256)3eff7b20e97ec975f75ca031f33a88bbf868a883144a59b62cf1763019e5fefa
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi